KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Laguerre, Brigitte
Arija, Jose Angel Arranz
Oudard, Stephane
Fong, Peter C. C.
Kolinsky, Michael Paul
Augustin, Marinela
Feyerabend, Susan
Kam, Audrey E.
Gurney, Howard
Tafreshi, Ali
Retz, Margitta
Berry, William R.
Mar, Nataliya
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Barcelona, Spain
[3] CLCC Inst Paoli Calmettes, Paris, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Hosp Gregorio Maranon, Madrid, Spain
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Auckland City Hosp, Auckland, New Zealand
[8] Cross Canc Inst, Edmonton, AB, Canada
[9] Paracelsus Med Univ, Nurnberg, Germany
[10] Studienpraxis Urol, Nurtingen, Germany
[11] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Univ Wollongong, Wollongong, NSW, Australia
[14] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[15] Duke Canc Ctr Cary, Cary, NC USA
[16] UCI Hlth, Orange, CA USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    Todenhoefer, T.
    Piulats, J. M.
    Ferrario, C.
    Linch, M. D.
    Stoeckle, M.
    Laguerre, B.
    Arranz, J. A.
    Fong, P. C. C.
    Berry, W. R.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A. M.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    De Bono, J. S.
    Yu, E. Y.
    EUROPEAN UROLOGY, 2022, 81 : S789 - S790
  • [22] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [23] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [24] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Wu, Haiyan
    Schloss, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Fer, Tilman Todenho Spacing Diaeresis
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Saretsky, Todd L.
    Ghate, Sameer R.
    Li, Xin Tong
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [26] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Goh, Jeffrey C. H.
    Ojamaa, Kristiina
    Rodriguez, Jose Maria Piulats
    Drake, Charles G.
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
  • [29] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [30] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony M.
    Linch, Mark David
    Kolinsky, Michael Paul
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345